-+ 0.00%
-+ 0.00%
-+ 0.00%

NextCure posts Phase 1 SIM0505 dose-escalation presentation slides

PUBT·06/02/2026 13:34:35
Listen to the news
NextCure posts Phase 1 SIM0505 dose-escalation presentation slides
  • NextCure published virtual KOL event slides with initial Phase 1 dose-escalation results for SIM0505, a CDH6-targeted antibody-drug conjugate.
  • At therapeutic doses of 4.8-8.0 mg/kg, gynecologic cancers showed a 55% ORR at 12 weeks and best response.
  • Ovarian cancer ORR was 52.9% (9/17); uterine serous carcinoma ORR was 66.7% (2/3).
  • Across 59 patients dosed 1.6-9.6 mg/kg, grade 3 or higher TEAEs occurred in 54.2%; grade 3 or higher TRAEs occurred in 47.5%.
  • Dose optimization started in 2Q 2026, testing 5.6, 6.4, 7.2 mg/kg every three weeks; a pivotal trial in platinum-resistant ovarian cancer is being planned.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.